Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 18 Closing remarks Solid leadership positions and continued market opportunities 27% Novo Nordisk value market share in diabetes care and solid leadership position ~5% insulin market volume growth 45% >21% 54% Novo Nordisk insulin volume market share with leadership position across all regions GLP-1 volume market growth 38% Novo Nordisk GLP-1 volume market share with global leadership position SaxendaⓇ value market share with a global leadership in the anti obesity market Promising pipeline and product launches • The only company with a full portfolio of novel insulin and GLP-1 products • . Semaglutide portfolio offers expansion opportunity with both once-weekly OzempicⓇ and oral administration XultophyⓇ supports promising outlook for insulin and GLP-1 combination therapy • SaxendaⓇ and multiple clinical stage development projects hold potential within obesity • Broad pipeline within haemophilia Source: IQVIA MAT Feb 2018 volume and value (DKK) figures changing diabetes novo nordisk

View entire presentation